New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
1. A new study supports CEL-SCI's early approval strategy for Multikine. 2. The findings published in 'Cancer Cell' could influence CVM stock positively.